POST Online Media Lite Edition


Agios Pharmaceuticals appoints CFO

Staff Writer |
Cambridge, Mass., USA - August 17, 2016, Cambridge, Mass., USA - Agios Pharmaceuticals, a pharmaceutical company, announced that Andrew Hirsch is joining the company as chief financial officer from September 19, 2016.

Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.

Prior to being named president and chief executive officer at BIND, he held several other leadership positions at the company, including chief operating officer and chief financial officer.

Prior to joining BIND, Mr. Hirsch was chief financial officer at Avila Therapeutics until its acquisition by Celgene and held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including vice president of Corporate Strategy and M&A and program executive for the Tecfidera development team.

LATEST 5 MOVES FROM Massachusetts 

What to read next

Agios Pharmaceuticals names chief commercial officer
Blueprint Medicines appoints Marion Dorsch as CSO
Agios Pharma names Ian Clark to board of directors